TELCYTA® (Canfosfamide HCl) is an investigational drug that is a cancer cell-activated chemotherapeutic. It was designed to exploit the elevated levels of glutathione S-transferase P1-1 (GST P1-1), an enzyme overexpressed in many human cancer cells. High levels of GST P1-1 are associated with a poor prognosis and resistance to certain chemotherapeutic drugs in tumors.
Preclinical studies suggest the activation of TELCYTA® occurs when GST P1-1 splits TELCYTA® into two active fragments: a glutathione analog fragment and an active cytotoxic fragment. The cytotoxic fragment reacts with important cell components, including RNA, DNA and proteins, leading to cell death. The glutathione analog fragment of TELCYTA® may remain bound to GST P1-1, which may limit the ability of GST P1-1 to inactivate other cancer drugs. The results of preclinical studies suggest that TELCYTA® is synergistic when combined with important chemotherapeutic drugs including platinums, taxanes and anthracyclines. Recent advances in the biology and mechanism of action for TELCYTA® have recently been reported.
TELCYTA® has been the subject of multiple Phase 2 and Phase 3 clinical trials in advanced cancers. It has shown clinical activity in advanced ovarian, non-small cell lung, colon and breast cancers. Recent publications document some of the activity of TELCYTA® in clinical trials.
We are evaluating our clinical data to assess the utility of TELCYTA® in additional cancers. Additional studies will need to be completed prior to a potential regulatory submission and the company is currently pursuing corporate partners to help in the further development of TELCYTA®.